Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)

BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX) is a promising antibody partner for anti-human epidermal growth factor receptor 2 (HER2). We performed neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer (BC) using nab-PTX plus trastuzumab (T-mab) and pertuzumab (P-mab), follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Futamura, Manabu, Ishihara, Kazuhiro, Nagao, Yasuko, Ogiso, Atsuko, Niwa, Yoshimi, Nakada, Takumi, Kawaguchi, Yoshihiro, Ikawa, Ai, Kumazawa, Iwao, Mori, Ryutaro, Kitazawa, Mai, Hosono, Yoshiki, Kuno, Masashi, Kawajiri, Mana, Nakakami, Akira, Takeuchi, Makoto, Morikawa, Akemi, Tokumaru, Yoshihisa, Katagiri, Yasuo, Asano, Yoshimasa, Mushika, Yoshinori, Shimokawa, Toshio, Matsuhasih, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950177/
https://www.ncbi.nlm.nih.gov/pubmed/36609911
http://dx.doi.org/10.1007/s12282-022-01425-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950177/
https://www.ncbi.nlm.nih.gov/pubmed/36609911
http://dx.doi.org/10.1007/s12282-022-01425-2

Ejemplares similares